On May 24, 2023 Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial-stage oncology company, reported that the SAPPHIRE study did not meet its primary endpoint of overall survival at the final analysis (Press release, Mirati, MAY 24, 2023, View Source [SID1234631998]). SAPPHIRE is a Phase 3 study evaluating sitravatinib in combination with nivolumab (OPDIVO)1 versus docetaxel in patients with second or third line advanced non-squamous non-small cell lung cancer (NSQ-NSCLC) who progressed on prior therapy with chemotherapy and immune checkpoint inhibitor therapy. The company plans to disclose the study data at a future date.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Principal Investigators will be given the option to continue therapy for patients who are experiencing clinical benefit and would like to remain on treatment.

"Mirati extends gratitude to the patients who participated in this clinical trial, their loved ones, and the trial investigators, without whom important work like this would not have been possible," said Alan Sandler, M.D., Chief Medical Officer. "As we move forward, we are optimistic about our ability to positively impact the lives of patients living with cancer through the advancement of our broad and differentiated pipeline of targeted oncology programs."